Transitional Care Program for HIV, Hepatitis C, and Substance Use Disorders

(CJC-TraC Trial)

Recruiting in Palo Alto (17 mi)

+2 other locations

Overseen by Ryan Westergaard, MD, PhD, MPH

Age: 18+

Sex: Any

Travel: May Be Covered

Time Reimbursement: Varies

Trial Phase: Academic

Waitlist Available

Sponsor: University of Wisconsin, Madison

No Placebo Group

Trial Summary

What is the purpose of this trial?

This trial tests a program called CJC-TraC that helps people leaving prison get the medical care they need. It focuses on those with HIV, Hepatitis C, or substance misuse history. The program coordinates their medical care to ensure they continue treatment after release. New treatments have made it easier and faster to cure Hepatitis C.

Research Team

Ryan Westergaard, MD, PhD, MPH

Principal Investigator

UW School of Medicine and Public Health

Eligibility Criteria

This trial is for incarcerated individuals in Wisconsin who are eligible for Medicaid and will be released within 6 months. They must understand English, plan to stay in Wisconsin post-release, and have HIV, Hepatitis C or a history of substance misuse.

Inclusion Criteria

Plans to reside in Wisconsin after release

Able to understand and speak in English

Eligible for Wisconsin Medicaid and willing to enroll prior to release

Exclusion Criteria

Planned discharge to another correctional facility or other carceral setting (e.g. release to jail or immigration detention center)

I am able to understand and make decisions about my health care.

Treatment Details

Interventions

• CJC-TraC (Behavioural Intervention)

Trial Overview The study tests the Coordinated Transitional Care intervention (CJC-TraC) adapted for those transitioning from incarceration back into society. It focuses on people with HIV, Hepatitis C or substance use disorders over a period of up to 6 months.

Participant Groups

Group I: CJC-TraC Intervention Experimental Treatment 1 Intervention

Incarcerated individuals with HIV, hepatitis C, or substance use disorder readying for release will enroll in the CJC-TraC intervention intended to assist in transitioning their health care.

Who Is Running the Clinical Trial?

University of Wisconsin, Madison

Lead Sponsor

Trials

1,249

Recruited

3,255,000+

Robert Drape

University of Wisconsin, Madison

Chief Executive Officer since 2007

Executive MBA from the University of Wisconsin – Madison, Bachelor's degree in Biology from Augustana College (IL)

Dr. Ciara Barclay-Buchanan

University of Wisconsin, Madison

Chief Medical Officer since 2023

MD from Wayne State University School of Medicine

National Institute on Drug Abuse (NIDA)

Collaborator

Trials

2,658

Recruited

3,409,000+

Dr. Nora Volkow

National Institute on Drug Abuse (NIDA)

Chief Executive Officer since 2003

MD from National Autonomous University of Mexico

Dr. Nora Volkow

National Institute on Drug Abuse (NIDA)

Chief Medical Officer since 2003

MD from National Autonomous University of Mexico